View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPalatin Technologies 배당 및 자사주 매입배당 기준 점검 0/6Palatin Technologies 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-178.0%자사주 매입 수익률총 주주 수익률-178.0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 14Palatin Technologies, Inc. to Report Q3, 2026 Results on May 13, 2026Palatin Technologies, Inc. announced that they will report Q3, 2026 results on May 13, 2026공시 • Nov 06Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $15.799999 million.Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $15.799999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,430,769 Price\Range: $6.5 Security Name: Series J Common Warrants Security Type: Equity Warrant Securities Offered: 2,430,769 Security Name: Series K Common Warrants Security Type: Equity Warrant Securities Offered: 2,430,769 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 2,430,769공시 • Oct 01Palatin Technologies, Inc. has filed a Follow-on Equity Offering.Palatin Technologies, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,492,537 Security Name: Series J Common Warrants Security Type: Equity Warrant Securities Offered: 1,492,537 Security Name: Series K Common Warrants Security Type: Equity Warrant Securities Offered: 1,492,537 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 1,492,537공시 • Jul 15Palatin Technologies, Inc. Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of ObesityPalatin Technologies, Inc. announced strong preclinical results for PL7737, an oral selective melanocortin-4 receptor (MC4R) agonist, showing effectiveness in rodent models of obesity. The preclinical study evaluated the weight loss effects of three oral doses of PL7737, both alone and in combination with tirzepatide (a GLP-1/GIP agonist), in a diet-induced obese (DIO) rat model. After 4 days of treatment, all results were statistically significant compared to vehicle control: PL7737 - Middle Dose: 5% weight loss, PL7737 - High Dose: 10% weight loss, Tirzepatide Alone: 5% weight loss,PL7737 Middle Dose + Tirzepatide: 11% weight loss. PL7737 High Dose + TirzepATide: 15% weight loss. Earlier this year, Palatin reported positive Phase 2 results from a study evaluating the combination of bremelanotide (an MC4R agonist) and tirzepatide (a GLP-1/G IP agonist). The study met its primary endpoint over the 8-week treatment period with highly statistically significant results. Additionally, Palatin announced that the FDA granted orphan drug designation to PL7737 for the treatment of leptin receptor (LEPR) deficiency-related obesity, a rare genetic disorder that disrupts MC4R signaling due to mutations in the LEPR gene. The leptin-melanocortin pathway, located in the hypothalamus, regulates hunger, energy balance, and body weight.공시 • Jul 10Nyse American LLC Affirms the Decision of the Staff of NYSE American to Initiate Delisting Proceedings of the Palatin Technologies, Inc. Common StockOn July 7, 2025, Palatin Technologies, Inc. received written notification from NYSE American LLC stating that a Listing Qualifications Panel of the Exchange’s Committee for Review had unanimously determined to affirm the decision of the staff of NYSE American to initiate delisting proceedings of the Company’s common stock pursuant to Sections 1003(a) and 1003(f)(v) of the NYSE American Company Guide. A hearing on the proposed delisting was held before the Panel on June 18, 2025. The Company intends to exercise its right to have the full Committee for Review reconsider the Panel’s decision. A written request for such review must be submitted and received by the Exchange within 15 calendar days of the date of Panel’s written notification. The Company is actively working to resolve the NYSE American listing deficiencies prior to the appeal hearing before the full Committee for Review, which is expected to take place in late August or September 2025.공시 • Jun 19Palatin Technologies, Inc., Annual General Meeting, Jul 25, 2025Palatin Technologies, Inc., Annual General Meeting, Jul 25, 2025.공시 • Jun 14Palatin Technologies, Inc. announced that it has received $0.34 million in fundingOn June 13, 2025, Palatin Technologies, Inc. closed the transaction.Board Change • May 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. Independent Director Tony Manning was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 PTN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: PTN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Palatin Technologies 배당 수익률 vs 시장PTN의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PTN)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Biotechs)2.2%분석가 예측 (PTN) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PTN 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PTN 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PTN 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: PTN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/11/05 23:13종가2025/08/08 00:00수익2025/06/30연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Palatin Technologies, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Scott HenryAlliance Global PartnersJohn NewmanCanaccord GenuityI-Eh JenLaidlaw & Company (UK) Ltd4명의 분석가 더 보기
공시 • May 14Palatin Technologies, Inc. to Report Q3, 2026 Results on May 13, 2026Palatin Technologies, Inc. announced that they will report Q3, 2026 results on May 13, 2026
공시 • Nov 06Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $15.799999 million.Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $15.799999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,430,769 Price\Range: $6.5 Security Name: Series J Common Warrants Security Type: Equity Warrant Securities Offered: 2,430,769 Security Name: Series K Common Warrants Security Type: Equity Warrant Securities Offered: 2,430,769 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 2,430,769
공시 • Oct 01Palatin Technologies, Inc. has filed a Follow-on Equity Offering.Palatin Technologies, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,492,537 Security Name: Series J Common Warrants Security Type: Equity Warrant Securities Offered: 1,492,537 Security Name: Series K Common Warrants Security Type: Equity Warrant Securities Offered: 1,492,537 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 1,492,537
공시 • Jul 15Palatin Technologies, Inc. Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of ObesityPalatin Technologies, Inc. announced strong preclinical results for PL7737, an oral selective melanocortin-4 receptor (MC4R) agonist, showing effectiveness in rodent models of obesity. The preclinical study evaluated the weight loss effects of three oral doses of PL7737, both alone and in combination with tirzepatide (a GLP-1/GIP agonist), in a diet-induced obese (DIO) rat model. After 4 days of treatment, all results were statistically significant compared to vehicle control: PL7737 - Middle Dose: 5% weight loss, PL7737 - High Dose: 10% weight loss, Tirzepatide Alone: 5% weight loss,PL7737 Middle Dose + Tirzepatide: 11% weight loss. PL7737 High Dose + TirzepATide: 15% weight loss. Earlier this year, Palatin reported positive Phase 2 results from a study evaluating the combination of bremelanotide (an MC4R agonist) and tirzepatide (a GLP-1/G IP agonist). The study met its primary endpoint over the 8-week treatment period with highly statistically significant results. Additionally, Palatin announced that the FDA granted orphan drug designation to PL7737 for the treatment of leptin receptor (LEPR) deficiency-related obesity, a rare genetic disorder that disrupts MC4R signaling due to mutations in the LEPR gene. The leptin-melanocortin pathway, located in the hypothalamus, regulates hunger, energy balance, and body weight.
공시 • Jul 10Nyse American LLC Affirms the Decision of the Staff of NYSE American to Initiate Delisting Proceedings of the Palatin Technologies, Inc. Common StockOn July 7, 2025, Palatin Technologies, Inc. received written notification from NYSE American LLC stating that a Listing Qualifications Panel of the Exchange’s Committee for Review had unanimously determined to affirm the decision of the staff of NYSE American to initiate delisting proceedings of the Company’s common stock pursuant to Sections 1003(a) and 1003(f)(v) of the NYSE American Company Guide. A hearing on the proposed delisting was held before the Panel on June 18, 2025. The Company intends to exercise its right to have the full Committee for Review reconsider the Panel’s decision. A written request for such review must be submitted and received by the Exchange within 15 calendar days of the date of Panel’s written notification. The Company is actively working to resolve the NYSE American listing deficiencies prior to the appeal hearing before the full Committee for Review, which is expected to take place in late August or September 2025.
공시 • Jun 19Palatin Technologies, Inc., Annual General Meeting, Jul 25, 2025Palatin Technologies, Inc., Annual General Meeting, Jul 25, 2025.
공시 • Jun 14Palatin Technologies, Inc. announced that it has received $0.34 million in fundingOn June 13, 2025, Palatin Technologies, Inc. closed the transaction.
Board Change • May 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. Independent Director Tony Manning was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.